-
公开(公告)号:US20180127413A1
公开(公告)日:2018-05-10
申请号:US15573141
申请日:2016-05-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Claude A. QUESNELLE , Lalgudi S. Harikrishnan , Matthew D. Hill
IPC: C07D471/04 , A61P35/02
Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
-
公开(公告)号:US20250163104A1
公开(公告)日:2025-05-22
申请号:US18715382
申请日:2022-12-02
Applicant: Bristol-Myers Squibb Company
Inventor: Jennifer X. QIAO , Michael A. POSS , Martin Patrick ALLEN , Claudio MAPELLI , Claude A. QUESNELLE , David R. TORTOLANI , Tammy C. WANG , Tao WANG , Yong ZHANG , Yunhui ZHANG , Zhongxing ZHANG
Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-